Management of bladder cancer: Current and emerging strategies

Drugs

Volumn 69, Issue 9, 2009, Pages 1173-1187

  Agarwal, Neeraj ^a   Hussain, Maha ^b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPOTHILONE DERIVATIVE; FLUOROURACIL; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; IXABEPILONE; METHOTREXATE; PACLITAXEL; PEMETREXED; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; ROMIDEPSIN; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINFLUNINE; VORINOSTAT;

ADJUVANT THERAPY; ADVANCED CANCER; ALOPECIA; ANEMIA; BLADDER CARCINOMA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; COLORECTAL CANCER; CYSTECTOMY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HUMAN; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; REVIEW; SENSORY NEUROPATHY; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; HUMANS; NEOPLASM METASTASIS; URINARY BLADDER NEOPLASMS;

EID: 67649313813     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-200969090-00003     Document Type: Review

References (107)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008 Mar-Apr; 58 (2): 71-96
2. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemo-therapy for patients with metastatic urothelial tumors. J Clin Oncol 1990 Jun; 8 (6): 1050-5
3. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000 Sep; 18 (17): 3068-77
4. Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 2006 Aug; 24 (3): 296-304
5. Lee CT. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol 2006; 175: 1262-7
6. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349 (9): 859-66
7. Collaboration ABCM-a. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999 Aug 14; 354 (9178): 533-40
8. Hall R. Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer [abstract 710]. Proc Am Soc Clin Oncol 2002; 21
9. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005 Aug; 48 (2): 202-25
10. Dash A, Pettus 4th JA, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008 Nov 1; 113 (9): 2471-7
11. Weight CJ, Garcia JA, Hansel DE, et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer 2009 Feb 15; 115 (4): 792-9
12. Skinner DG. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145: 459-67
13. Stockle M, Meyenburg W, Wellek S, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992 Aug; 148 (2 Pt 1): 302-36
14. Stockle M, Meyenburg W, Wellek S, et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995 Jan; 153 (1): 47-52
15. Cognetti F, Ruggeri EM, Felici A, et al. Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC): an Italian multicenter randomised phase III trial [abstract no. 5023]. J Clin Oncol 2008 May 20; 26 (15S)
16. Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol 2005; 48: 189-201
17. Loehrer Sr PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992 Jul; 10 (7): 1066-73
18. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997 Jul; 15 (7): 2564-9
19. von derMaase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005 Jul 20; 23 (21): 4602-8
20. Siefker-Radtke AO, Millikan RE, Tu SM, et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002 Mar 1; 20 (5): 1361-7
21. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001 May 15; 19 (10): 2638-46
22. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006 Jan; 42 (1): 50-4
23. Bamias A, Aravantinos G, Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004 Jan 15; 22 (2): 220-8
24. von der Maase H, Andersen L, Crino L, et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 1999 Dec; 10 (12): 1461-5
25. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000 May; 18 (9): 1921-7
26. Moore MJ, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999 Sep; 17 (9): 2876-81
27. Bellmunt J, Ribas A, Eres N, et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997 Nov 15; 80 (10): 1966-72
28. Petrioli R, Frediani B, Manganelli A, et al. Comparison between a cisplatin-containing regimen and a carboplatincontaining regimen for recurrent or metastatic bladder cancer patients: a randomized phase II study. Cancer 1996 Jan 15; 77 (2): 344-51
29. Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004 Apr 15; 100 (8): 1639-45
30. Dogliotti L, Carteni G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007 Jul; 52 (1): 134-41
31. Li J, Juliar B, Yiannoutsos C, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 2005 Feb 20; 23 (6): 1185-91
32. Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001 Jun 15; 19 (12): 3018-24
33. Parameswaran R, Fisch MJ, Ansari RH, et al. A Hoosier Oncolgy Group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell (TCC) carcinoma of the bladder [abstract 798]. Proc Am Soc Clin Oncol 2001; 20: 200a
34. Gitlitz BJ, Baker C, Chapman Y, et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 2003 Nov 1; 98 (9): 1863-9
35. Ardavanis A, Tryfonopoulos D, Alexopoulos A, et al. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer 2005 Feb 28; 92 (4): 645-50
36. Bellmunt J, Guillem V, Paz-Ares L, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000 Sep 15; 18 (18): 3247-55
37. Bajorin DF, McCaffrey JA, Dodd PM, et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 2000 Apr 1; 88 (7): 1671-8
38. Hussain M, Vaishampayan U, Du W, et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001 May 1; 19 (9): 2527-33
39. Pectasides D, Glotsos J, Bountouroglou N, et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol 2002 Feb; 13 (2): 243-50
40. Lara Jr PN, Meyers FJ, Law LY, et al. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma. Cancer 2004 Jan 1; 100 (1): 82-8
41. Bellmunt J, von der Maase H, Mead G, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. J Clin Oncol ASCO Annu Meet Proc Part 1 2007; 25 (18S): LBA5030
42. McCaffrey JA, Hilton S, MazumdarM, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997 May; 15 (5): 1853-7
43. Papamichael D, Gallagher CJ, Oliver RT, et al. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997; 75 (4): 606-7
44. Vaughn DJ, Broome CM, Hussain M, et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002 Feb 15; 20 (4): 937-40
45. Lorusso V, Pollera CF, AntimiM, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998 Jul; 34 (8): 1208-12
46. Witte RS, Elson P, Bono B, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997 Feb; 15 (2): 589-93
47. Sternberg CN, Calabro F, Pizzocaro G, et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001 Dec 15; 92 (12): 2993-8
48. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004 May 15; 22 (10): 2015-25
49. Dreicer R, Li S,Manola J, et al. Phase 2 trial of epothilone B analogBMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer 2007 Aug 15; 110 (4): 759-63
50. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006 May 22; 94 (10): 1395-401
51. Vaughn D, Srinivas S, Petrylak DP, et al. Vinflunine (VFL) in patients with platinum-refractory transitional cell carcinoma of the urothelium (TCCU): results of a large phase 2 study [abstract 316]. Genitourinary Cancers Symposium; 2009 Feb 14; San Francisco
52. Bellmunt J, VonderMass H, Theodore C. et al. Randomized phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2nd line therapy after a platinumcontaining regimen in advanced transitional cell carcinoma of the urothelium (TCC). ASCO Annual Meeting; 2008 May 30-Jun 3; Chicago
53. Galsky MD, Mironov S, Iasonos A, et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest N Drugs 2007 Jun; 25 (3): 265-70
54. Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006 Jul 20; 24 (21): 3451-7
55. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer: therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003 Jun 27; 46 Suppl.: S85-104
56. Rajkumar T, Stamp GW, Pandha HS, et al. Expression of the type 1 tyrosine kinase growth factor receptors EGF receptor, c-erbB2 and c-erbB3 in bladder cancer. J Pathol 1996 Aug; 179 (4): 381-5
57. Sriplakich S, Jahnson S, Karlsson MG. Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer? BJU Int 1999 Mar; 83 (4): 498-503
58. Chow NH, Liu HS, Lee EI, et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 1997 Mar-Apr; 17 (2B): 1293-6
59. Cardillo MR, Castagna G, Memeo L, et al. Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer. J Exp Clin Cancer Res 2000 Jun; 19 (2): 225-33
60. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994 Jun; 69 (6): 1120-5
61. Nguyen PL, Swanson PE, Jaszcz W, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder: a multivariate survival analysis. Am J Clin Pathol 1994 Feb; 101 (2): 166-76
62. Mellon K, Wright C, Kelly P, et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 1995 Mar; 153 (3 Pt 2): 19-925
63. Kassouf W, Black PC, Tuziak T, et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 2008 Jan; 179 (1): 353-8
64. Crew JP. Vascular endothelial growth factor: an important angiogenic mediator in bladder cancer. Eur Urol 1999 Jan; 35 (1): 2-8
65. Slaton JW, Millikan R, Inoue K, et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 2004 Feb; 171 (2 Pt 1): 570-4
66. Goddard JC, Sutton CD, Furness PN, et al. Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res 2003 Jul; 9 (7): 2583-6
67. Canoglu A, Gogus C, Beduk Y, et al. Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. Int Urol Nephrol 2004; 36 (3): 401-5
68. Dominguez-Escrig JL, Kelly JD, Neal DE, et al. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004 Jul 15; 10 (14): 4874-84
69. McHugh LA, Kriajevska M, Mellon JK, et al. Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens: evidence of scheduledependent synergy. Urology 2007 Feb; 69 (2): 390-4
70. University of Michigan. Study of gemcitabine and cisplatin with or without cetuximab in urothelial cancer [Clinical-Trials.gov identifier NCT00645593]. US National Institutes of Health, ClinicalTrials.gov [online]. Available fromURL: http://www.clinicaltrials.gov [Accessed 2009 May 12]
71. Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and LeukaemiaGroup B 90102. BJU Int 2008 Jan; 101 (1): 20-5
72. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 May 12; 244 (4905): 707-12
73. Lonn U, Lonn S, Friberg S, et al. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995 Oct; 1 (10): 1189-94
74. Jimenez RE, Hussain M, Bianco Jr FJ, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001 Aug; 7 (8): 2440-7
75. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007 Jun 1; 25 (16): 2218-24
76. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999 Oct; 17 (10): 3173-81
77. Sonpavde G, Jian W, LiuH, et al. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol. Epub 2008 Jun 3
78. Gallagher D, MilowskyMI, Gerst SR, et al. Final results of a phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC) [abstract 5082]. J Clin Oncol 2008 May; 26: (20 Suppl.)
79. Bradley DA, Dunn R, Nanus D, et al. Randomized, doubleblind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer 2007 Dec; 5 (7): 460-3
80. University of Michigan. Trial of maintenance SUO11248 versus placebo post chemotherapy for patients with advanced urothelial carcinoma [ClinicalTrials.gov identifier NCT00393796]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 May 12]
81. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001 Dec; 1 (3): 194-202
82. Kelly WK, O'Connor OA, Marks PA. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 2002 Dec; 11 (12): 1695-713
83. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003 Sep 1; 9 (10 Pt 1): 3578-88
84. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005 Jun 10; 23 (17): 3923-31
85. Buckley MT, Yoon J, Yee H, et al. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med 2007; 5: 49
86. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002 Mar; 8 (3): 718-28
87. Omerovic J, Laude AJ, Prior IA. Ras proteins: paradigms for compartmentalised and isoform-specific signalling. Cell Mol Life Sci 2007 Oct; 64 (19-20): 2575-89
88. Ayan S, Gokce G, Kilicarslan H, et al. K-RAS mutation in transitional cell carcinoma of urinary bladder. Int Urol Nephrol 2001; 33 (2): 363-7
89. Cattan N, Saison-Behmoaras T, Mari B, et al. Screening of human bladder carcinomas for the presence of Ha-ras codon 12 mutation. Oncol Rep 2000 May-Jun; 7 (3): 497-500
90. Saito S, Hata M, Fukuyama R, et al. Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. Int J Urol 1997 Mar; 4 (2): 178-85
91. Rosenberg JE, von der Maase H, Seigne JD, et al. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 2005 May 15; 103 (10): 2035-41
92. Winquist E, Moore MJ, Chi KN, et al. A multinomial phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol 2005 May-Jun; 23 (3): 143-9
93. Theodore C, Geoffrois L, Vermorken JB, et al. Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor and gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer 2005 May; 41 (8): 1150-7
94. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004 May; 4 (5): 349-60
95. Karin M, Yamamoto Y,Wang QM. The IKKNF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004 Jan; 3 (1): 17-26
96. Gomez-Abuin G, Winquist E, Stadler WM, et al. A phase II study of PS-341 (bortezomib) in advanced or metastatic urothelial cancer: a trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Invest N Drugs 2007 Apr; 25 (2): 181-5
97. Rosenberg JE, Halabi S, Sanford BL, et al. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann Oncol 2008 May; 19 (5): 946-50
98. Vaughn DJ. Chemotherapeutic options for cisplatinineligible patients with advanced carcinoma of the urothelium. Cancer Treat Rev 2008 Jun; 34 (4): 328-38
99. Freyer G, Geay JF, Touzet S, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 2005 Nov; 16 (11): 1795-800
100. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-smallcell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 2005 Oct 1; 23 (28): 6865-72
101. Hurria A, Gupta S, Zauderer M, et al. Developing a cancerspecific geriatric assessment: a feasibility study. Cancer 2005 Nov 1; 104 (9): 1998-2005
102. Rao AV, Hsieh F, Feussner JR, et al. Geriatric evaluation and management units in the care of the frail elderly cancer patient. J Gerontol A Biol Sci Med Sci 2005 Jun; 60 (6): 798-803
103. Linardou H, Aravantinos G, Efstathiou E, et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-Operative Oncology Group. Urology 2004 Sep; 64 (3): 479-84
104. Bellmunt J, deWit R, Albanell J, et al. A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer. Eur J Cancer 2001 Nov; 37 (17): 2212-5
105. De Santis M, Bellmunt J,Mead B, et al. Randomized phase II/III study assessing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in previously untreated patients (pts) with advanced urothelial cancer ineligible for cisplatin based chemotherapy: phase II results [abstract 288]. Genitourinary Cancers Symposium; 2009 Feb 14; San Francisco
106. Ricci S, Galli L, Chioni A, et al. Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens. Cancer 2002 Oct 1; 95 (7): 1444-50
107. Turkolmez K, Beduk Y, Baltaci S, et al. Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy. Eur Urol 2003 Dec; 44 (6): 682-6